Author Archives: admin


Stem Cell Clinic > Articles by: admin

ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer…

By Global News Feed

Poster presentation will highlight new data from clinical trial evaluating evorpacept, a highly differentiated investigational CD47 blocker, in combination with zanidatamab, an investigational dual HER2-targeted bispecific antibody, in patients with advanced breast cancers Poster presentation will highlight new data from clinical trial evaluating evorpacept, a highly differentiated investigational CD47 blocker, in combination with zanidatamab, an investigational dual HER2-targeted bispecific antibody, in patients with advanced breast cancers

Visit link:
ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer...

Belite Bio Announces Exercise of Warrants for US$28.75 Million Gross Proceeds

By Global News Feed

SAN DIEGO, Nov. 03, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announces the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 651,380 ordinary shares of the Company originally issued in April 2024, at an exercise price of US$44.14 per share. The gross proceeds to the Company from the exercise of the warrants are expected to be approximately US$28.75 million. The Company intends to use the net proceeds from the offering for general corporate purposes.

More here:
Belite Bio Announces Exercise of Warrants for US$28.75 Million Gross Proceeds

Telix Welcomes CMS Decision to Improve Payments for Diagnostic Radiopharmaceuticals

By Global News Feed

MELBOURNE, Australia, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today welcomes the announcement by the United States (U.S.) Centers for Medicare & Medicaid Services (CMS) that it will pay separately for specialized diagnostic radiopharmaceuticals1 for Medicare Fee for Service patients in the hospital outpatient setting, beyond the transitional pass-through payment period (“pass-through”). This is a significant decision for patients and hospitals, with the change facilitating equitable access to advanced imaging agents for all patients into the future.

Follow this link:
Telix Welcomes CMS Decision to Improve Payments for Diagnostic Radiopharmaceuticals

OSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase 2 Study of Anti-IL7R mAb Lusvertikimab for…

By Global News Feed

OSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase 2 Study of Anti-IL7R mAb Lusvertikimab for the Treatment of Ulcerative Colitis

Continued here:
OSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase 2 Study of Anti-IL7R mAb Lusvertikimab for...

QIAGEN receives FDA clearance of QIAstat-Dx meningitis/encephalitis panel to support emergency diagnostics

By Global News Feed

QIAstat-Dx Meningitis/Encephalitis Panel cleared in the U.S. for use in clinical settings to help diagnose central nervous system infections // Fourth FDA clearance marks milestone in 2024 in successful expansion of QIAstat?Dx tests developed specifically for the U.S. // QIAGEN now offers broad menu with FDA-cleared tests for respiratory, gastrointestinal and central nervous system infections – and plans for further expansion // QIAstat-Dx delivers results in about one hour with real-time PCR, ensuring fast and accurate results to support clinical decision-making QIAstat-Dx Meningitis/Encephalitis Panel cleared in the U.S. for use in clinical settings to help diagnose central nervous system infections // Fourth FDA clearance marks milestone in 2024 in successful expansion of QIAstat?Dx tests developed specifically for the U.S. // QIAGEN now offers broad menu with FDA-cleared tests for respiratory, gastrointestinal and central nervous system infections – and plans for further expansion // QIAstat-Dx delivers results in about one hour with real-time PCR, ensuring fast and accurate results to support clinical decision-making

View original post here:
QIAGEN receives FDA clearance of QIAstat-Dx meningitis/encephalitis panel to support emergency diagnostics

Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies

By Stem Cell Clinic

SOUTH SAN FRANCISCO, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL) announced today that it has entered into a definitive agreement to acquire ImmPACT Bio USA Inc. (“ImmPACT”), a privately-owned clinical-stage biotechnology company. ImmPACT’s lead program, IMPT-314, is a CD19/20-targeting chimeric antigen receptor (CAR) T-cell product candidate that Lyell will continue to develop for hematologic malignancies, including large B-cell lymphoma. IMPT-314 was designed to outperform the efficacy of approved CD19 CAR T-cell therapies via a dual-targeting CAR T-cell design and to improve CAR T-cell persistence by enriching for naïve and central memory T cells during manufacturing. The acquisition of ImmPACT is expected to significantly strengthen Lyell’s clinical-stage pipeline of next- generation CAR T-cell therapies and complement its suite of proprietary technologies designed to generate longer-lasting, functional T cells to achieve more durable outcomes for patients with solid tumors and hematologic malignancies.

Read this article:
Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies

Ardelyx Shares Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) at the American Society of Nephrology’s Kidney Week

By Stem Cell Clinic

WALTHAM, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that data supporting additional positive clinical observations of XPHOZAH® (tenapanor) was presented in a series of poster presentations at the American Society of Nephrology’s (ASN) Kidney Week, currently taking place in San Diego. Ardelyx is also hosting an Exhibitor Spotlight discussing hyperphosphatemia management.

See the original post:
Ardelyx Shares Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) at the American Society of Nephrology’s Kidney Week

TELA Bio Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase…

By Stem Cell Clinic

MALVERN, Pa., Oct. 24, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction, today announced the closing of its previously announced underwritten public offering of 14,670,000 shares of its common stock, including the exercise in full of the underwriters’ option to purchase additional shares, at a price to the public of $2.25 per share and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase 5,800,000 shares of common stock at a public offering price of $2.2499 per pre-funded warrant, which represents the per share public offering price for the shares of common stock less the $0.0001 per share exercise price for each pre-funded warrant, for gross proceeds of $46 million, before deducting underwriting discounts and commissions and other estimated offering expenses and assuming no exercise of the pre-funded warrants. All shares of common stock and pre-funded warrants were sold by TELA.

Continued here:
TELA Bio Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase...

→←